Research & Development
We are driven by clinical questions rather than specific biomarker classes or technologies. Hence, we are using a range of sophisticated omics technologies for biomarker identification and validation. Going forward, these technologies will also be used for diagnostic testing services provided by our lab in Cologne, Germany and potentially also by a future US reference laboratory. For our final IVD products we rely on established IVD technologies with widely used instrument platforms where we partner with established industry players.
Product Pipeline
In parallel to exploring alternative diagnostic solutions for the reliable early detection of HIE – historically the focus of the Company - we are pursuing further novel opportunities in prenatal testing and infant health with the intention of creating a high-value portfolio that balances biological, technological, and market risks.

Due to ongoing partnering discussions and intellectual property-related activities, further details will be disclosed in the near future.